BiomX Inc. (PHGE) recently announced the presentation of data from its Phase 1b/2a study for BX004 — a fixed multi-phage cocktail. BX004 is used for treating cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas aeruginosa (PsA).BiomX will present this study data at the North American Cystic Fibrosis Conference in Boston.PHGE Stock’s Likely Trend Following the NewsShares of PHGE rose 2.8% to $1.05 yesterday following the news. To date, BX004 has been under several trials. It ...